Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIAOU6)

Drug Name

SLN124 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Beta thalassemia	3A50.2	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting TMPRSS6 messenger RNA (TMPRSS6 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IONIS-TMPRSS6-LRx	DM7VJE1	Beta thalassemia	3A50.2	Phase 2	[3]
Sapablursen	DM95T5Z	Polycythemia vera	2A20.4	Phase 2	[4]
ALN-TMP	DMW7XEU	Beta thalassemia	3A50.2	Preclinical	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TMPRSS6 messenger RNA (TMPRSS6 mRNA)	TTNIUKC	TMPS6_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04718844) A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
2	SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1. Hemasphere. 2019 Oct 1;3(6):e301.
3	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
4	Clinical pipeline report, company report or official report of Ionis
5	Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423.